Clinical Trial Update: Functional Imaging in the Assessment of mRCC Response to Sunitinib [NA]

View source ↗

Summary

A clinical trial evaluating functional imaging to assess metastatic renal cell carcinoma response to sunitinib has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Imperial College Healthcare NHS Trust | Conditions: Metastatic Renal Cell Carcinoma | NA | Status: WITHDRAWN